Odyssey Health, Inc. (OTCMKTS:ODYY), formerly known as Odyssey Group International, Inc., is pleased to welcome Vice Admiral (r) Timothy Szymanski to its prestigious Military Advisory Board. The company is presently working to develop a proprietary drug compound to treat concussion.
On Wednesday, ODYY stock moved up 2.10% to $0.48 with 6K shares, compared to its average volume of 34K shares. The stock moved within a range of $0.4779 – 0.4893 after opening trade at $0.4779.
Odyssey Health Welcomes United States Vice Admiral (r) Timothy Szymanski to Military Advisory Board
Vice Admiral (r) Szymanski has led and served in many Navy and Joint Special Operations assignments as a Navy Special Warfare Officer (SEAL) for more than three decades. Most recently, he served Deputy Commander for United States Special Operations Command (USSOCOM) after serving as the Commander of Naval Special Warfare (NSW). In both roles he was responsible for the manning, equipping, and training, and employment of Navy SEAL and joint special operations forces, of 11,000 and 73,000 uniformed and civilian personnel, respectively.
Odyssey’s drug candidate, PRV-002 is currently in a phase 1 clinical trial. Statistics show that up to 3.8 million people in the United States experience a concussion each year. It is also estimated that from 30% to 50% of concussions are unreported and untreated.
Among them, several service members and veterans suffer constantly from post-concussive events, while their families are affected too, as they watch and provide care. There is an urgent need for a concussion treatment at the point of injury that immediately treats the initial injury, accelerates recovery, and potentially diminishes its long-term effects. Odyssey aims to accomplish that by pursuing treatments that improve a service member’s, and their families’ well-being.
“Too many service members and veterans are suffering from post-concussive events, while their families are suffering as they watch and provide care. There remains an urgent need for a concussion treatment at the point of injury that immediately treats the initial injury, speeds recovery, and potentially diminishes its long-term effects. We are obligated to pursue treatments that improve a service member’s, and their families’, well-being through their service commitment and beyond.”
ODYY stock is trading below the 20-Day and 50-Day Moving averages of $0.49 and $0.50 respectively. Moreover, the stock is trading is the oversold zone with RSI stands at 48.